Market Closed -
Deutsche Boerse AG
07:20:01 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
29.1
EUR
|
+1.39%
|
|
+1.75%
|
-5.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
785.5
|
1,126
|
1,609
|
1,520
|
1,456
|
1,395
|
-
|
Enterprise Value (EV)
1 |
1,135
|
1,525
|
2,035
|
2,047
|
2,038
|
2,056
|
2,058
|
P/E ratio
|
-186
x
|
-36
x
|
-24.3
x
|
-43
x
|
9.63
x
|
-284
x
|
19.2
x
|
Yield
|
0.2%
|
0.14%
|
0.1%
|
0.12%
|
0.13%
|
0.07%
|
2.15%
|
Capitalization / Revenue
|
1.87
x
|
2.33
x
|
3.12
x
|
2.94
x
|
2.13
x
|
2.19
x
|
1.96
x
|
EV / Revenue
|
2.71
x
|
3.15
x
|
3.95
x
|
3.97
x
|
2.98
x
|
3.23
x
|
2.89
x
|
EV / EBITDA
|
37.2
x
|
53.9
x
|
-127
x
|
107
x
|
11.4
x
|
37.4
x
|
13.9
x
|
EV / FCF
|
-16,766,519
x
|
-34,894,916
x
|
-
|
-29,327,274
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
1.7
x
|
2.52
x
|
4.02
x
|
3.63
x
|
2.46
x
|
3.99
x
|
3.43
x
|
Nbr of stocks (in thousands)
|
39,571
|
39,571
|
39,571
|
39,571
|
39,571
|
39,571
|
-
|
Reference price
2 |
20.50
|
28.10
|
38.60
|
34.00
|
31.00
|
28.90
|
28.90
|
Announcement Date
|
30/03/20
|
31/03/21
|
24/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
419.1
|
484.2
|
515.6
|
516.1
|
684.6
|
635.8
|
712.1
|
EBITDA
1 |
30.5
|
28.3
|
-16
|
19.2
|
179.4
|
54.91
|
147.7
|
EBIT
1 |
-1.2
|
-1.3
|
-47.1
|
16.6
|
143.5
|
15.9
|
106.8
|
Operating Margin
|
-0.29%
|
-0.27%
|
-9.13%
|
3.22%
|
20.96%
|
2.5%
|
15%
|
Earnings before Tax (EBT)
1 |
-1.3
|
-30
|
-62.6
|
-30.8
|
106.3
|
-5.677
|
83.75
|
Net income
1 |
-4.7
|
-31.4
|
-63.4
|
-31.7
|
127
|
-4.031
|
59.46
|
Net margin
|
-1.12%
|
-6.48%
|
-12.3%
|
-6.14%
|
18.55%
|
-0.63%
|
8.35%
|
EPS
2 |
-0.1100
|
-0.7800
|
-1.590
|
-0.7900
|
3.220
|
-0.1019
|
1.503
|
Free Cash Flow
|
-67.7
|
-43.7
|
-
|
-69.8
|
-
|
-
|
-
|
FCF margin
|
-16.15%
|
-9.03%
|
-
|
-13.52%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0400
|
0.0400
|
0.0400
|
0.0400
|
0.0400
|
0.0200
|
0.6210
|
Announcement Date
|
30/03/20
|
31/03/21
|
24/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
350
|
399
|
427
|
528
|
582
|
661
|
663
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
11.46
x
|
14.1
x
|
-26.68
x
|
27.47
x
|
3.242
x
|
12.04
x
|
4.49
x
|
Free Cash Flow
|
-67.7
|
-43.7
|
-
|
-69.8
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
19.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
12.10
|
11.20
|
9.610
|
9.380
|
12.60
|
7.250
|
8.440
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
34.1
|
27
|
-
|
29.3
|
-
|
-
|
-
|
Capex / Sales
|
8.14%
|
5.58%
|
-
|
5.68%
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
31/03/21
|
24/03/22
|
23/03/23
|
28/03/24
|
-
|
-
|
Last Close Price
28.9
EUR Average target price
37
EUR Spread / Average Target +28.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.46% | 86.16B | | +2.76% | 40.17B | | -17.49% | 31.47B | | +54.44% | 25.24B | | -13.13% | 15.82B | | -9.12% | 11.96B | | -15.45% | 11.89B | | -42.56% | 11.61B | | +4.87% | 8.84B |
Biopharmaceuticals
|